FDA Accepted New Drug Application for Achondroplasia
The regulatory review for an oral therapy for children with achondroplasia is now underway.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Should companies be incentivized to develop high-cost treatments for rare genetic conditions?
The FDA has accepted the New Drug Application for oral infigratinib, an investigational treatment for children with achondroplasia. The agency also granted the application Priority Review status, setting a target action date of February 4, 2027.
Why it matters
The FDA prioritized this application due to the significant unmet need for an oral therapeutic option for the condition. This development marks a shift toward potential new treatment pathways for children with open growth plates.
In the Phase 3 PROPEL 3 study, patients demonstrated a mean treatment difference of 2.10 cm/year in annualized height velocity at 52 weeks. The LS mean treatment difference for the cohort was 1.74 cm/year.
The players
BridgeBio
A clinical-stage biopharmaceutical company headquartered in Palo Alto, California, focused on developing genetic medicines for rare diseases.
FDA
The United States federal agency responsible for regulating new drug applications and ensuring therapeutic efficacy.
The details
Achondroplasia is a form of dwarfism caused by an activating variant in the FGFR3 gene. Oral infigratinib works by inhibiting FGFR3 signaling, a process that aims to improve bone growth. The study measured the change from baseline in annualized height velocity at 52 weeks to determine the efficacy of the intervention.
Timeline
Week 52: Measurement of change in annualized height velocity.
Q4 2026: Planned submission of Marketing Authorization Application to the EMA.
February 4, 2027: PDUFA target action date for FDA decision.
The Tech Race
This regulatory filing follows the success of the Phase 3 PROPEL 3 study, which met its primary endpoint. The development positions this oral inhibitor within a competitive landscape of emerging genetic therapies for achondroplasia.
The therapy is intended for the estimated 10,000 children and adolescents with achondroplasia who have open growth plates. Availability in the U.S. remains pending federal approval and the conclusion of the priority review period.
The takeaway
The FDA’s acceptance of this application highlights the urgency in developing oral treatments for rare genetic skeletal conditions. Interested parties should watch for the EMA submission in late 2026 and the final FDA decision on February 4, 2027.
What happens next
BridgeBio intends to submit a Marketing Authorization Application to the European Medicines Agency in the fourth quarter of 2026, followed by the FDA's target decision date on February 4, 2027.
Further reading
For broader trends in genetic medicine, visit our Biotech section.
Live Poll
Should companies be incentivized to develop high-cost treatments for rare genetic conditions?
